Aerococcus viridans: Introduction, Morphology, Pathogenicity, Lab Diagnosis, Treatment, Prevention, and Keynotes

Introduction

Aerococcus viridans is a gram-positive coccus that rarely infects humans. It usually inhabits hospital environments. Moreover, it exists in air and water. It causes urinary tract infections, endocarditis, and bacteremia. Additionally, it appears in various clinical specimens. Furthermore, laboratories sometimes misidentify it as viridans streptococci. It remains catalase-negative and oxidase-negative. Consequently, clinicians face diagnostic challenges. Also, advanced methods now improve its identification. Finally, understanding its characteristics enhances clinical management.

Morphology

A. viridans appears as gram-positive cocci. It forms distinctive tetrads and irregular clusters. Moreover, it shows a morphology resembling viridans streptococci.

It grows as small, creamy, alpha-hemolytic colonies. Additionally, the bacterium is catalase-negative in routine tests. It thrives in microaerophilic and facultatively anaerobic environments. Furthermore, it exhibits a smooth colony surface on blood agar.

Also, its arrangement confounds traditional identification methods. Consequently, it requires careful observation in the lab.

Pathogenicity

Aerococcus viridans causes opportunistic infections in predisposed individuals. It frequently triggers urinary tract infections in compromised hosts. Moreover, it causes endocarditis by invading heart tissues. It also produces bacteremia in vulnerable patients. Additionally, the bacterium can rarely infect joints and meninges. Furthermore, it expresses virulence factors that enable host colonization. It resists some immune defenses and multiplies quickly. Consequently, infections may worsen without proper treatment. Also, clinicians must consider its pathogenic potential.

Lab Diagnosis

Aerococcus viridans emerges as gram-positive cocci under microscopic examination. It forms small colonies on blood agar that appear alpha-hemolytic. Furthermore, clinical laboratories often face misidentification challenges.

They use catalase and oxidase tests to distinguish it. Additionally, biochemical methods provide useful clues. Moreover, advanced techniques like MALDI-TOF MS improve accuracy.

They also applied 16S rRNA sequencing for confirmation. Consequently, careful analysis helps differentiate it from similar organisms.

Treatment

Clinicians treat Aerococcus viridans with beta-lactam antibiotics. They often use penicillin or ampicillin as first-line therapy. Furthermore, vancomycin serves as a good alternative. They choose ceftriaxone in some cases of resistance. Additionally, treatment in endocarditis requires prolonged intravenous therapy. Moreover, combining an aminoglycoside may enhance the effect. Clinicians always perform antibiotic susceptibility testing. Consequently, treatment adapts to the infection’s severity.

Prevention

• Medical teams prevent Aerococcus viridans infections by ensuring prompt diagnosis.
• They implement strict hygiene practices in healthcare settings.
• Furthermore, they conduct routine screening in high-risk patients.
• Additionally, rapid identification methods reduce diagnostic delays.
• Moreover, they apply careful antibiotic stewardship to limit resistance.
• Healthcare workers follow strict disinfection protocols.
• They use personal protective equipment during sample handling.
• Consequently, early intervention curtails the spread of this pathogen.

Keynotes

• Aerococcus viridans is a rarely reported but significant pathogen.
• It is a gram-positive coccus that forms tetrads and clusters.
• Moreover, it remains catalase-negative and oxidase-negative.
• It causes urinary tract infections, endocarditis, and bacteremia.
• Additionally, its identification poses diagnostic challenges.
• Furthermore, advanced methods like MALDI-TOF MS enhance accuracy.
• Clinicians treat it with beta-lactam antibiotics and vancomycin.
• Consequently, prompt and accurate diagnosis improves outcomes.
• Overall, Aerococcus viridans represents an emerging organism that demands clinical awareness.

Further Readings

• https://en.wikipedia.org/wiki/Aerococcus_viridans
• https://en.wikipedia.org/wiki/Aerococcus
• https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(15)00896-4/pdf
• https://pmc.ncbi.nlm.nih.gov/articles/PMC6530520/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC6530520/
• https://www.mayoclinicproceedings.org/article/S0025-6196(12)60342-5/fulltext
• https://journal.chestnet.org/article/S0012-3692(21)01845-6/fulltext
• https://www.sciencedirect.com/science/article/pii/S1198743X15008964
• https://www.sciencedirect.com/science/article/pii/S2468550X22001940
• https://www.cabidigitallibrary.org/doi/pdf/10.5555/20210015521
• https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/aerococcus-viridans
• https://pubmed.ncbi.nlm.nih.gov/33157289/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC3852453/
• https://afju.springeropen.com/articles/10.1186/s12301-022-00327-1
• https://pmc.ncbi.nlm.nih.gov/articles/PMC5393163/
• https://www.sciencedirect.com/science/article/pii/S1201971220323018
• https://pmc.ncbi.nlm.nih.gov/articles/PMC5393163/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC6530520/
• https://www.merckmanuals.com/professional/infectious-diseases/gram-positive-cocci/enterococcal-infections